Efficacy and Safety of Epidural Chloroprocaine for Breakthrough Pain During Labor Analgesia: A Prospective, Double-Blind, Randomized Trial

• DOI: 10.1007/s40122-024-00577-7
• Publication Date: 2024-02-01T08:03:05Z
• Authors: Tianzhen Ji; Can Jiang; Hongxia Liu; Zhehao Cai; Rongrong Liu; Lei Xie; Cheng Xu
• Keywords: Ropivacaine; Sufentanil

A significant number of women who undergo neuraxial labor analgesia experience breakthrough pain. Prompt mitigation pain is essential to improve maternal and fetal outcomes. We evaluated epidural chloroprocaine compared with ropivacaine in alleviating performed a double-blind randomized controlled clinical trial between May July 2023. Eligible parturients received sufentanil. Those were receive either 0.125% (group R) or at concentrations 0.5% C1), 1.0% C2), 1.5% C3), all volume 6 mL. The primary outcome was the treatment success rate, indicated by decrease least 4 points on numerical rating scale score 9 min after analgesic injection. Secondary outcomes adverse effects also recorded. Out 323 patients receiving analgesia, 192 experienced After exclusion three because protocol deviation, there 47, 48, 47 group R, C1, C2, C3, respectively. Group C3 demonstrated higher rate (39/47, 83.0%) managing than R (26/47, 55.3%), C1 (12/48, 25.0%), C2 (30/47, 63.8%) (p < 0.001). had lower scores injection required fewer patient-controlled boluses other groups. In addition, reported greater satisfaction groups No differences observed obstetric neonatal across these Parturients experiencing could chloroprocaine, rather ropivacaine, achieve more rapid better relief patient satisfaction. Chinese Clinical Trial Registry, ChiCTR2300071069, http://www.chictr.org.cn/index.aspx .